AIM Puts mRNA Covid Vaccine in Investor Crosshairs With New IPO Attempt

Vaccine maker’s previous IPO bids on Shenzhen’s ChiNext board and in Hong Kong failed, but it is soldiering ahead with a new attempt in Hong Kong Key takeaways: Vaccine maker AIM has filed for an IPO in Hong Kong, following unsuccessful previous bids in Hong Kong and on Shenzhen’s ChiNext board The company has three Covid vaccines under development, including an mRNA vaccine expected to hit the market in the fourth quarter By Fai Pui If at first you don’t succeed, try, try again. And again. And again. That’s the mantra…

Read More »

FAST NEWS: Covid Vaccine Maker Sinovac’s Profit Skyrockets in First Financial Report for 2021

The latest: Sinovac Biotech Ltd. (SVA.US), maker of one of China’s three major Covid-19 vaccines, reported its revenue soared 161 times to $11 billion (70 billion yuan) in the first six months of 2021 from $67.7 million a year earlier, according to a Thursday stock exchange filing. The company said it posted a $5.1 billion profit for the period, or $44.80 per diluted share, compared to a $12.6 million loss in the year-ago period. Looking Up: Sinovac said it has supplied over 2.5 billion doses of its CoronaVac vaccine for…

Read More »

Greatly Transformed Sinovac Set to Reawaken on Wall Street?

Maker of the CoronaVac vaccine for Covid-19 could soon resume trading on the Nasdaq after a nearly three-year pause, following two key legal developments Key takeaways: Two key legal developments could soon pave the way for a resumption of trading in shares of Nasdaq-listed Sinovac, ending a nearly three-year suspension Company’s revenue may have risen 80-fold or more since the suspension thanks to sales of its globally accepted CoronaVac Covid-19 vaccine By Doug Young By now, many people have heard of Sinovac Biotech Ltd. (SVA.US), the maker of one of…

Read More »

Pandemic Accelerates China’s Drive Into mRNA Treatments

Messenger RNA-based technology that is highly effective in preventing Covid-19 can also be used for treatment of other diseases Key points: High efficacy rates in preventing Covid-19 spark rush by Chinese companies into mRNA vaccines and treatments At least one Chinese-made mRNA Covid vaccine, backed by the military, is now in late-stage development  By Richard Barbarossa They may be late to the party, but that hasn’t stopped China’s drug makers from rushing into messenger RNA (mRNA) drug-making technology, which has won global fame for its use in creating highly effective…

Read More »